NASD · Healthcare · Biotechnology · USA
Biomarin Pharmaceutical Inc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
BioMarin Pharmaceutical is a rare disease biotechnology company that develops and markets medicines for genetically defined conditions. The company offers eight commercial therapies across enzyme replacement, genetic, and other treatment modalities for conditions including mucopolysaccharidosis, phenylketonuria, hemophilia, achondroplasia, and neuronal ceroid lipofuscinosis. It operates globally with manufacturing, research, and commercial operations serving patients with serious rare and life-threatening diseases.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Biomarin Pharmaceutical Inc stock.
Overvalued: intrinsic value $19.12 per share, market price $58.51, margin of safety -206.1% (as of 2026-10-30).
Discounting its cash flows at 6.8% (average of 2 methods) values the shares at $19.12; the price of $58.51 is 206% above that value, and 84% of that value comes from beyond year five.
Leak Score: 56/100 on 11 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
67 more in this industry show a wider margin of safety.
BMRN is overvalued (as of the 2026-10-30 close). Discounting its cash flows at 6.8% (average of 2 methods) values the shares at $19.12; the price of $58.51 is 206% above that value, and 84% of that value comes from beyond year five.
$19.12 per share (as of the 2026-10-30 close), against a market price of $58.51. That is a margin of safety of -206.1%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
56 out of 100, which we rate "Weak Signal", on 11 of 12 value investing signals.